Dow Jones component Merck hiked its 2026 outlook Thursday on the back of a solid third-quarter report that included a notable Keytruda beat. The post Merck Beats, But Can Shares Outplay The Cancer Vaccine News? appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real